Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Proef om de veiligheid en effectiviteit van mechanische ondersteuning van de bloedsomloop te evalueren bij patiënten met voortschrijdend hartfalen (TEAM-HF)

3 november 2026 bijgewerkt door: Abbott Medical Devices

The purpose of TEAM-HF IDE clinical trial is to evaluate safety and effectiveness of the HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of ambulatory advanced heart failure patients who are not dependent on intravenous inotrope.

Studie Overzicht

Gedetailleerde beschrijving

Patients with heart failure (HF) suffer from a high degree of morbidity and mortality. Left ventricular assist device (LVAD) therapy has become the standard of care for the treatment of advanced HF patients who are deemed to be dependent on continuous intravenous inotropes, extending life expectancy, enhancing overall quality of life, and improving functional capacity. However, use of LVADs in ambulatory, non-inotrope dependent advanced HF population is limited. Elevated mean pulmonary artery pressure (PAP) secondary to left ventricular failure has emerged as a potential predictor of increased mortality risk for patients refractory to maximally tolerated guideline directed medical therapy (GDMT). In these patients, left ventricular failure with elevated mean PAP may represent objective criteria to identify advanced HF patients requiring heart replacement therapies such as LVAD.

The TEAM-HF IDE trial will enroll approximately 850 subjects with New York Heart Association (NYHA) Class IIIB/IV HF who had a prior heart failure hospitalization and an elevated mean PAP secondary to left ventricular failure. Elevated mean PAP will be identified using an implanted PAP monitoring sensor, the CardioMEMS PA Sensor. All subjects enrolled can have a previously implanted CardioMEMS PA Sensor or, if not, will be implanted with the CardioMEMS PA Sensor after enrollment. The overall objectives of TEAM-HF trial are two-fold: 1) To determine whether PAP can objectively identify patients most at risk for worsening HF and therefore most likely to benefit from earlier intervention with LVAD therapy and 2) To determine the benefit of LVAD therapy in non-inotrope advanced HF patients with elevated mean PAP refractory to GDMT.

The trial will include approximately 75 global sites and consists of a Randomized Arm and a Single Arm Registry.

The TEAM-HF Randomized Arm is a prospective, randomized, open-label study of the HeartMate 3 (HM3) left ventricular assist system (LVAS) versus continued GDMT in non-inotrope dependent HF patients. The objectives of the Randomized Arm are 1) To establish an objective disease-state criteria to trigger referral for a HM3 LVAS and 2) Demonstrate improvement in survival when non-inotrope dependent advanced HF patients are treated with the HM3 LVAS compared to being managed on medical therapy alone.

The TEAM-HF Single Arm Registry is a prospective, single-arm, open-label study of non-inotrope dependent HF patients who do not meet a mean PAP threshold after GDMT optimization. The objective of the Single Arm Registry is to characterize the progression of patients with non-inotrope dependent HF without elevated PAP.

Studietype

Ingrijpend

Inschrijving (Geschat)

850

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

    • Copenhagen
      • Copenhagen, Copenhagen, Denemarken, 2100
        • Werving
        • Rigshospitalet
        • Contact:
        • Hoofdonderzoeker:
          • Kasper Rossing, MD
    • Saxon
      • Hanover, Saxon, Duitsland, 30625
        • Werving
        • Medizinische Hochschule Hannover
        • Hoofdonderzoeker:
          • Dominik Berliner, MD
        • Contact:
    • Saxony
    • State of Berlin
      • Berlin, State of Berlin, Duitsland, 13353
        • Werving
        • Deutsches Herzzentrum der Charité
        • Hoofdonderzoeker:
          • Felix Schoenrath, MD
        • Contact:
    • Piedmont
      • Turin, Piedmont, Italië, 10126
        • Werving
        • A.O.U. Citta della Salute e della Scienza di Torino
        • Contact:
        • Hoofdonderzoeker:
          • Antonino Loforte, MD
    • Holland
      • Rotterdam, Holland, Nederland, 3015 CE
        • Werving
        • Erasmus MC - Thoraxcenter
        • Contact:
        • Hoofdonderzoeker:
          • Rudolf De Boer, MD
    • Utrecht
      • Utrecht, Utrecht, Nederland, 3584 CX
        • Werving
        • UMC Utrecht
        • Hoofdonderzoeker:
          • Linda Van Laake, MD
        • Contact:
    • State of Vienna
      • Vienna, State of Vienna, Oostenrijk, 1090
        • Werving
        • AKH -Wien
        • Contact:
        • Hoofdonderzoeker:
          • Daniel Zimpfer, MD
    • Riyadh Region
      • Riyadh, Riyadh Region, Saoedi-Arabië, 11525
        • Werving
        • King Fahad Medical City
        • Hoofdonderzoeker:
          • Mohammed Alreshidan, MD
        • Contact:
      • Riyadh, Riyadh Region, Saoedi-Arabië, 12713
        • Werving
        • King Faisal Specialist Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Jehad Abdulhamid Al Buraiki, MD
    • CBohmia
      • Prague, CBohmia, Tsjechië, 14021
        • Werving
        • IKEM Prague
        • Hoofdonderzoeker:
          • Ivan Netuka, MD
        • Contact:
    • Arizona
      • Phoenix, Arizona, Verenigde Staten, 85006
        • Ingetrokken
        • Banner-University Medical Center Phoenix
    • Arkansas
      • Little Rock, Arkansas, Verenigde Staten, 72205
        • Werving
        • Baptist Health Medical Center
        • Hoofdonderzoeker:
          • Patrick Campbell, MD
        • Contact:
    • California
      • Sacramento, California, Verenigde Staten, 95816
        • Werving
        • Sutter Medical Center
        • Contact:
        • Hoofdonderzoeker:
          • Michael Gibson, MD
      • San Francisco, California, Verenigde Staten, 94143
        • Werving
        • University of California at San Francisco
        • Contact:
        • Hoofdonderzoeker:
          • Shweta Motiwala, MD
    • District of Columbia
      • Washington D.C., District of Columbia, Verenigde Staten, 20010
        • Werving
        • Washington Hospital Center
        • Hoofdonderzoeker:
          • Sheikh Farooq, MD
        • Contact:
    • Florida
      • Gainesville, Florida, Verenigde Staten, 32610
        • Werving
        • Shands at the University of Florida
        • Hoofdonderzoeker:
          • Mustafa Ahmed, MD
        • Contact:
      • Weston, Florida, Verenigde Staten, 33331
        • Werving
        • Cleveland Clinic Florida
        • Contact:
        • Hoofdonderzoeker:
          • Mauricio Velez, MD
    • Georgia
      • Atlanta, Georgia, Verenigde Staten, 30309
        • Werving
        • Piedmont Heart Institute
        • Hoofdonderzoeker:
          • Catherine Marti, MD
        • Contact:
      • Augusta, Georgia, Verenigde Staten, 30901
        • Werving
        • Piedmont Augusta Hospital
        • Hoofdonderzoeker:
          • Darshak Karia, MD
        • Contact:
      • Marietta, Georgia, Verenigde Staten, 30060
    • Illinois
      • Chicago, Illinois, Verenigde Staten, 60637
        • Werving
        • University of Chicago
        • Contact:
        • Hoofdonderzoeker:
          • Nikhil Narang, MD
      • Oakbrook Terrace, Illinois, Verenigde Staten, 60181
        • Werving
        • Advocate Health & Hospitals Corporation
        • Contact:
        • Hoofdonderzoeker:
          • Vinh Chau, MD
    • Indiana
      • Indianapolis, Indiana, Verenigde Staten, 46240
        • Werving
        • St. Vincent Hospital
        • Hoofdonderzoeker:
          • Ashwin Ravichandran, MD
        • Contact:
    • Iowa
      • Iowa City, Iowa, Verenigde Staten, 52242
        • Werving
        • University of Iowa Hospitals & Clinics
        • Contact:
        • Hoofdonderzoeker:
          • Anthony Panos, MD
    • Kansas
      • Kansas City, Kansas, Verenigde Staten, 66160
        • Werving
        • Kansas University Medical Center
        • Contact:
        • Hoofdonderzoeker:
          • Zubair Shah, MD
    • Kentucky
      • Lexington, Kentucky, Verenigde Staten, 40536
        • Beëindigd
        • University of Kentucky
      • Louisville, Kentucky, Verenigde Staten, 40202
        • Werving
        • Norton Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Alkhalil Bassel, MD
    • Maine
      • Portland, Maine, Verenigde Staten, 04102
        • Werving
        • Maine Medical Center
        • Contact:
        • Hoofdonderzoeker:
          • Peter Kennel, MD
    • Massachusetts
      • Boston, Massachusetts, Verenigde Staten, 02114
        • Werving
        • Massachusetts General Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Erin Coglianese, MD
    • Michigan
      • Detroit, Michigan, Verenigde Staten, 48202
        • Werving
        • Henry Ford Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Lindsey Aurora, MD
      • Grand Rapids, Michigan, Verenigde Staten, 49503
        • Werving
        • Spectrum Health Butterworth Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Matthew Gonzalez, MD
    • Minnesota
      • Minneapolis, Minnesota, Verenigde Staten, 55407
        • Werving
        • Minneapolis Heart Institute
        • Hoofdonderzoeker:
          • Mosi Bennett, MD
        • Contact:
      • Rochester, Minnesota, Verenigde Staten, 55905
        • Werving
        • Mayo Clinic
        • Contact:
        • Hoofdonderzoeker:
          • Andrew Rosenbaum, MD
    • Missouri
      • Kansas City, Missouri, Verenigde Staten, 64111
        • Werving
        • St. Luke's Hospital
        • Hoofdonderzoeker:
          • Timothy Fendler, MD
        • Contact:
    • Nebraska
      • Omaha, Nebraska, Verenigde Staten, 68198
        • Werving
        • University of Nebraska Medical Center
        • Contact:
        • Hoofdonderzoeker:
          • Adam Burdorf, DO
    • New Jersey
      • Hackensack, New Jersey, Verenigde Staten, 07601
        • Werving
        • Hackensack University Medical Center
        • Hoofdonderzoeker:
          • Kanika Mody, MD
        • Contact:
      • Newark, New Jersey, Verenigde Staten, 07112
        • Werving
        • Newark Beth Israel Medical Center
        • Hoofdonderzoeker:
          • Igor Gosev, MD
        • Contact:
    • New Mexico
      • Albuquerque, New Mexico, Verenigde Staten, 87102
        • Werving
        • New Mexico Heart Institute
        • Contact:
        • Hoofdonderzoeker:
          • Dana Booth, MD
    • New York
      • Manhasset, New York, Verenigde Staten, 11030
        • Werving
        • North Shore University Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Maria Avila, MD
      • New York, New York, Verenigde Staten, 10032
        • Werving
        • New York-Presbyterian/Columbia University Medical Center
        • Contact:
        • Hoofdonderzoeker:
          • Dor Lotan, MD
      • Rochester, New York, Verenigde Staten, 14642
        • Werving
        • University of Rochester Medical Center
        • Contact:
        • Hoofdonderzoeker:
          • Leway Chen, MD
      • The Bronx, New York, Verenigde Staten, 10467
        • Werving
        • Montefiore Medical Center - Moses Campus
        • Hoofdonderzoeker:
          • Yogita Rochlani, MD
        • Contact:
    • North Carolina
      • Chapel Hill, North Carolina, Verenigde Staten, 27599
        • Werving
        • University of North Carolina at Chapel Hill
        • Contact:
        • Hoofdonderzoeker:
          • William Mostertz, MD
      • Charlotte, North Carolina, Verenigde Staten, 28203
        • Werving
        • Carolinas Medical Center
        • Contact:
        • Hoofdonderzoeker:
          • Joseph Mishkin, MD
    • Ohio
      • Cincinnati, Ohio, Verenigde Staten, 45219
      • Cleveland, Ohio, Verenigde Staten, 44195
        • Werving
        • The Cleveland Clinic Foundation
        • Contact:
          • Barbara Gus
          • Telefoonnummer: 216-445-6552
          • E-mail: gusb@ccf.org
        • Hoofdonderzoeker:
          • Michael Tong, MD
    • Oklahoma
      • Oklahoma City, Oklahoma, Verenigde Staten, 73112
        • Werving
        • Integris Baptist Medical Center
        • Contact:
        • Hoofdonderzoeker:
          • Luke Cunningham, MD
      • Tulsa, Oklahoma, Verenigde Staten, 74104
        • Werving
        • Oklahoma Heart Institute at Utica
        • Contact:
        • Hoofdonderzoeker:
          • Luis David Meggo Quiroz, MD
      • Tulsa, Oklahoma, Verenigde Staten, 74136
        • Werving
        • Saint Francis Hospital
        • Hoofdonderzoeker:
          • Douglas Ensley, MD
        • Contact:
    • Oregon
      • Portland, Oregon, Verenigde Staten, 97239
        • Werving
        • Oregon Health & Science University
        • Hoofdonderzoeker:
          • Johannes Steiner, MD
        • Contact:
    • Pennsylvania
      • Abington, Pennsylvania, Verenigde Staten, 19001
        • Werving
        • Abington Memorial Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Alexander Shpilman, MD
      • Hershey, Pennsylvania, Verenigde Staten, 17033
        • Werving
        • Penn State Milton S. Hershey Medical Center
        • Hoofdonderzoeker:
          • John Boehmer, MD
        • Contact:
      • Philadelphia, Pennsylvania, Verenigde Staten, 19104
      • Philadelphia, Pennsylvania, Verenigde Staten, 15213
        • Werving
        • University of Pittsburgh Medical Center (UPMC)
        • Hoofdonderzoeker:
          • Gavin Hickey, MD
        • Contact:
      • Pittsburgh, Pennsylvania, Verenigde Staten, 15212
        • Werving
        • Allegheny General Hospital
        • Hoofdonderzoeker:
          • Matthew Lander, MD
        • Contact:
    • South Carolina
      • Charleston, South Carolina, Verenigde Staten, 29425
        • Werving
        • Medical University of South Carolina
        • Hoofdonderzoeker:
          • Arman Kilic, MD
        • Contact:
      • Columbia, South Carolina, Verenigde Staten, 29203
    • Tennessee
      • Memphis, Tennessee, Verenigde Staten, 38120
        • Werving
        • The Stern Cardiovascular Foundation
        • Contact:
        • Hoofdonderzoeker:
          • Todd Edwards, MD
    • Texas
      • Austin, Texas, Verenigde Staten, 78705
        • Werving
        • Ascension Texas Cardiovascular
        • Contact:
        • Hoofdonderzoeker:
          • Raymond Bietry, MD
      • Dallas, Texas, Verenigde Staten, 75246
        • Werving
        • Baylor University Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Cesar Guerrero-Miranda, MD
      • Houston, Texas, Verenigde Staten, 77030
        • Werving
        • Houston Methodist
        • Contact:
        • Hoofdonderzoeker:
          • Cindy Martin, MD
      • Houston, Texas, Verenigde Staten, 77030
        • Werving
        • CHI St. Luke's Health Baylor College of Medicine Medical Center
        • Hoofdonderzoeker:
          • Ajith Nair, MD
        • Contact:
      • Houston, Texas, Verenigde Staten, 77030
        • Werving
        • UTHealth Memorial Hermann
        • Contact:
        • Hoofdonderzoeker:
          • Nathan Sriram, MD
      • Plano, Texas, Verenigde Staten, 75093
        • Werving
        • The Heart Hospital Baylor Plano
        • Contact:
        • Hoofdonderzoeker:
          • Aasim Afzal, MD
      • Temple, Texas, Verenigde Staten, 76508
        • Werving
        • Scott & White Memorial Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Yevgeniy Khariton, MD
    • Utah
      • Salt Lake City, Utah, Verenigde Staten, 84132
        • Werving
        • University of Utah Hospital
        • Hoofdonderzoeker:
          • Craig Selzman, MD
        • Contact:
    • Virginia
      • Charlottesville, Virginia, Verenigde Staten, 22908
        • Werving
        • University of Virginia Medical Center
        • Contact:
        • Hoofdonderzoeker:
          • Mirnela Byku, MD
      • Richmond, Virginia, Verenigde Staten, 23219
        • Werving
        • Virginia Commonwealth University
        • Hoofdonderzoeker:
          • Keyur Shah, MD
        • Contact:
    • Wisconsin
      • Milwaukee, Wisconsin, Verenigde Staten, 53215
        • Werving
        • Aurora Medical Group
        • Hoofdonderzoeker:
          • Nasir Sulemanjee, MD
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  1. Subject has provided written informed consent by signing the study Informed Consent Form (ICF) prior to any clinical investigation-related procedure
  2. LVEF ≤30% and Cardiac Index ≤ 2.5 L/min/m²
  3. Limited functional status as demonstrated by 6MWT ≤ 350 m due to HF related reasons OR peak VO2 ≤ 14 mL/kg/min (or <50% of predicted peak VO2 value)
  4. NYHA Class IIIB or NYHA Class IV
  5. Subject has ≥ 1 Heart Failure Hospitalization in the last 12 months
  6. Subject is already implanted with a CardioMEMS PA Sensor OR willing to undergo a CardioMEMS PA Sensor implant
  7. Subject is willing and able to be implanted with the HM3 LVAS if randomized to HM3 Group

Randomization Criteria:

  1. Subject has been implanted with a CardioMEMS PA Sensor for at least 90 days.
  2. Subject is receiving guideline directed medical therapy with optimal doses (or documented medication contraindication or intolerance) of betablockers, Angiotensin-Converting-Enzyme-inhibitors or Angiotensin II Receptor Blockers or angiotensin receptor neprilysin inhibitor (if eligible), Mineralocorticoid Receptor Antagonists, Sodium-Glucose co-Transporter-2 (SGLT2) inhibitors, and diuretics for at least 30 of the last 90 days.
  3. mean PAP ≥ 30 mmHg.
  4. The subject will not be randomized if they have any other factor that represents inordinate risk for either continued GDMT or LVAD implant.

Single Arm Registry Criteria:

  1. Subject has received a CardioMEMS PA Sensor implant following enrollment in the trial.
  2. Subject is receiving guideline directed medical therapy with optimal doses (or documented medication contraindication or intolerance) of betablockers, Angiotensin-Converting-Enzyme-inhibitors or Angiotensin II Receptor Blockers or angiotensin receptor neprilysin inhibitor (if eligible), Mineralocorticoid Receptor Antagonists, Sodium-Glucose co-Transporter-2 (SGLT2) inhibitors, and diuretics for at least 30 of the last 90 days.
  3. mean PAP <30 mmHg

Exclusion Criteria:

  1. Subject is < 18 years of age at the time of informed consent.

  2. Dependent on IV inotrope in the last 30 days.

  3. Contra-indications to HM3 LVAS or CardioMEMS HF system.

  4. Etiology of HF due to or associated with uncorrected thyroid disease, obstructive cardiomyopathy, pericardial disease, amyloidosis, or restrictive cardiomyopathy.

  5. Technical obstacles to LVAD or CardioMEMS implantation which pose an inordinately high surgical risk, in the judgment of the implanter.

  6. Existence of ongoing MCS.

  7. Presence of mechanical aortic valve that will not be either converted to a bioprosthesis or oversewn at the time of LVAD implant.

  8. History of any solid organ transplant.

  9. Psychiatric disease/disorder, irreversible cognitive dysfunction or psychosocial issues that are likely to impair compliance with the study protocol and LVAS management.

  10. Presence of an active, uncontrolled infection.

  11. Complex congenital heart disease.

  12. Currently Pregnant or capable of becoming Pregnant and Unwilling to Use Contraception with LVAD.

  13. History of pulmonary embolism within 30 days prior to enrollment or history of recurrent (>1 episode) pulmonary embolism and/or deep vein thrombosis.

  14. Planned VAD or Bi-VAD support prior to enrollment.

  15. Presence of any one of the following risk factors for or indications of severe end organ dysfunction or failure:

    1. An INR ≥ 2.0 not due to anticoagulation therapy
    2. An eGFR < 30 mL/min/1.73 m2 and nonresponsive to diuretic therapy or receiving chronic dialysis.
    3. Biopsy proven liver cirrhosis.
    4. Need for chronic renal replacement therapy.
    5. History of severe chronic obstructive pulmonary disease (COPD) defined by Forced Expiratory Volume FEV1 < 30% predicted.
    6. History of cerebrovascular disease with significant (> 80%) uncorrected internal carotid stenosis.
    7. Significant peripheral vascular disease (PVD) accompanied by ischemic rest pain or extremity ulceration.
  16. Any condition other than HF that could limit survival to less than 24 months.

  17. Participation in any other clinical investigation with an active treatment arm that is likely to confound study results or affect the study outcome.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Randomized Arm - HM3 Group

Patients with elevated mean PAP (mean PAP ≥ 30 mmHg) and randomized to the HM3 group will receive the device within 14 days of randomization.

The CardioMEMS™ HF System is comprised of a lead-less and battery-less pressure sensor which remotely transmits pulmonary artery pressure measurements.

Andere namen:
  • CardioMEMS
  • CardioMEMS PA-sensor

The HeartMate 3 LVAS is a mechanical circulatory support pump with Full MagLev Technology that assumes some or all of the workload of the left ventricle. The HeartMate 3 LVAS is used in advanced heart failure patients needing short or long-term mechanical circulatory support.

Andere namen:
  • HM3

Optimal doses of medical therapy per established heart failure guidelines which includes the following stable combination of Beta Blockers, ACE-inhibitors or ARB or ARNi, MRA and SGLT2 inhibitors.

Andere namen:
  • GDMT
Experimenteel: Randomized Arm - Control Group

Patients with elevated mean PAP (mean PAP ≥ 30 mmHg) and randomized to the control group will continue their medical therapy per established heart failure guidelines.

The CardioMEMS™ HF System is comprised of a lead-less and battery-less pressure sensor which remotely transmits pulmonary artery pressure measurements.

Andere namen:
  • CardioMEMS
  • CardioMEMS PA-sensor

Optimal doses of medical therapy per established heart failure guidelines which includes the following stable combination of Beta Blockers, ACE-inhibitors or ARB or ARNi, MRA and SGLT2 inhibitors.

Andere namen:
  • GDMT
Experimenteel: Single Arm Registry

Patients who do not meet the mean PAP threshold (mean PAP <30 mmHg) and are enrolled in the single arm will continue their medical therapy per established heart failure guidelines.

The CardioMEMS™ HF System is comprised of a lead-less and battery-less pressure sensor which remotely transmits pulmonary artery pressure measurements.

Andere namen:
  • CardioMEMS
  • CardioMEMS PA-sensor

Optimal doses of medical therapy per established heart failure guidelines which includes the following stable combination of Beta Blockers, ACE-inhibitors or ARB or ARNi, MRA and SGLT2 inhibitors.

Andere namen:
  • GDMT

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Survival at 2 years free of disabling stroke, reoperation to replace the device, or worsening HF requiring listing for urgent heart transplantation or mechanical circulatory support, enrollment into hospice, or dependence on IV inotropes
Tijdsspanne: 2 years

The powered primary endpoint will be analyzed at 2 years following the Com-Nougue method and will be compared between the HM3 Group (HM3 LVAD) and the Control Group (GDMT) within the Intention-to-treat (ITT) population.

2 years

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Rate of Safety Outcomes at 1-year
Tijdsspanne: 1 year

The powered secondary endpoint of Rate of Safety Outcomes at 1-year will be evaluated within the Intention-to-treat (ITT) population against a pre-specified performance goal.

Components consist of the following:

  1. Heart failure hospitalization

  2. Major Adverse Event (MAE) including:

    • Stroke
    • Non-surgical bleeding (>14 days post implant) requiring hospitalization
    • Renal failure requiring hospitalization
    • Driveline infection requiring hospitalization
1 year
Survival at 2 years
Tijdsspanne: 2 years

The powered secondary endpoint of survival at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population.

2 years
Quality of life score assessed with the Kansas City Cardiomyopathy Questionnaire
Tijdsspanne: 2 years

The secondary endpoint of Quality-of-life score at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the secondary endpoint of Quality of life at 2-years will be descriptively compared between the Single Arm Registry and both the HM3 Group and Control Group of the Randomized Arm separately.

The KCCQ scores are represented on a 0-to-100-point scale, where lower scores represent more severe symptoms and/or limitations and scores of 100 indicate no symptoms, no limitations, and excellent quality of life. Improvement of KCCQ by at least 10 points is considered clinically significant.

2 years
Six-minute walk distance
Tijdsspanne: 2 years

The secondary endpoint of six-minute walk distance at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the secondary endpoint of six-minute walk distance at 2-years will be descriptively compared between the Single Arm Registry and both the HM3 Group and Control Group of the Randomized Arm separately.

2 years
Hospitalizations for HF and/or Urgent HF Visit
Tijdsspanne: 2 years

The secondary endpoint of Hospitalizations for HF and/or Urgent HF Visit at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the secondary endpoint of Hospitalizations for HF and/or Urgent HF Visit at 2-years will be descriptively compared between the Single Arm Registry and both the HM3 Group and Control Group of the Randomized Arm separately.

2 years
Days alive and outside of the hospital
Tijdsspanne: 2 years

The secondary endpoint of days alive and outside of the hospital at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the secondary endpoint of days alive and outside of the hospital at 2-years will be descriptively compared between the Single Arm Registry and both the HM3 Group and Control Group of the Randomized Arm separately.

2 years
All-cause hospitalizations
Tijdsspanne: 2 years

The secondary endpoint of all-cause hospitalizations at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the secondary endpoint of all-cause hospitalizations at 2-years will be descriptively compared between the Single Arm Registry and both the HM3 Group and Control Group of the Randomized Arm separately.

2 years
All adverse events (including all strokes) regardless of severity
Tijdsspanne: 2 years

The secondary endpoint of all adverse events (including all strokes) regardless of severity at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the secondary endpoint of all adverse events (including all strokes) regardless of severity at 2-years will be descriptively compared between the Single Arm Registry and both the HM3 Group and Control Group of the Randomized Arm separately.

2 years

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Finkelstein-Schoenfeld Win Ratio
Tijdsspanne: 5 years

The Finkelstein-Schoenfeld Win Ratio will be explored at 5 years as an additional analysis with the following hierarchy:

  1. Survival
  2. Days alive outside of the hospital
  3. Quality of Life assessed with the KCCQ (considered a tie if within 10 points)
  4. Functional Capacity (Six-minute walk distance)

The Finkelstein-Schoenfeld Win Ratio will be analyzed between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the Finkelstein-Schoenfeld Win Ratio will be descriptively analyzed between the Single Arm and both the HM3 Group and Control Group of the Randomized Arm separately.

5 years
Survival free of urgent LVAD or transplant
Tijdsspanne: 5 years

This additional descriptive analysis at 5-years will be performed to evaluate the proportion of patients who are alive and free of device replacement or transplant in the HM3 Group compared to the Single Arm Registry (de novo implant or transplant)

5 years

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Studie directeur: Kelly O'Connell, PhD, Abbott

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

13 december 2024

Primaire voltooiing (Geschat)

1 september 2029

Studie voltooiing (Geschat)

1 september 2032

Studieregistratiedata

Eerst ingediend

24 juli 2024

Eerst ingediend dat voldeed aan de QC-criteria

24 juli 2024

Eerst geplaatst (Werkelijk)

29 juli 2024

Updates van studierecords

Laatste update geplaatst (Werkelijk)

5 november 2026

Laatste update ingediend die voldeed aan QC-criteria

3 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Ja

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren